Molecular diagnosis of prostate cancer: Topical issues

Molecular diagnosis of prostate cancer: Topical issues

Show other versions (1)

Prostate cancer (PC) is the second most common cancer and the fifth highest malignancy mortality rate in men worldwide. Although PC is detectable in 15-20% of men during life, its death risk is only about 3%. This means that not all PC cases require the same management tactics. The given review anal...

Full description

Bibliographic Details
Main Authors:	E. N. Knyazev, K. A. Fomicheva, K. M. Nyushko, A. D. Kaprin, B. Ya. Alekseev, M. Yu. Shkurnikov
Format:	Article
Language:	Russian
Published:	ABV-press 2014-12-01
Series:	Onkourologiâ
Subjects:	prostate cancer molecular genetic markers receptors membrane proteins heat shock protein transcriptome gene fusion matrix ribonucleic acids prostate cancer antigen 3 polymerase chain reaction expression hyperactivation
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/391

Similar Items

Molecular diagnosis of prostate cancer: Topical issues
by: E. N. Knyazev, et al.
Published: (2014-12-01)

Application of loop-mediated isothermal amplification of DNA for diagnosis of prostate cancer micrometastases in the lymph nodes
by: M. Yu. Shkurnikov, et al.
Published: (2017-06-01)

Prostate-Specific antigen: An overview and its current status in the diagnosis of prostate cancer
by: Siddalingeshwar Neeli, et al.
Published: (2021-01-01)

Use of immunohistochemical markers in clinical-morphological diagnostic of prostate diseases
by: Grygorieva J. V.
Published: (2010-01-01)

Circulating microRNA expression in connection with prostate cancer lymphogenous metastasis
by: M. Yu. Shkurnikov, et al.
Published: (2018-04-01)

Identification of Specific Long Non-Coding Ribonucleic Acid Signatures and Regulatory Networks in Prostate Cancer in Fine-Needle Aspiration Biopsies
by: Zehuan Li, et al.
Published: (2020-02-01)

Moving ahead of prostate-specific antigen
by: Banyameen Mohamad Iqbal, et al.
Published: (2016-01-01)

Association of prostate volume with incidence and aggressiveness of prostate cancer
by: Al-Khalil S, et al.
Published: (2016-10-01)

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
by: Arslaan Javaeed, et al.
Published: (2020-05-01)

Clinical Issues for Prostate-Specific Antigen Screening: A Narrative Review
by: Marco Randazzo, et al.
Published: (2018-12-01)

The results of transrectal prostate biopsy in patients with low levels of prostate specific antigen
by: Ahmet Ali Sancaktutar, et al.
Published: (2012-06-01)

Prostate Specific Antigen (PSA): The Historical Perspective
by: T. Ming Chu
Published: (2020-12-01)

Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers
by: Matthew J. Roberts, et al.
Published: (2016-09-01)

Diagnostic value of PCA3, TMPRSS2:ERG and prostatic specific antigen derivatives in the detection of prostate cancer
by: A. A. Musaelyan, et al.
Published: (2020-07-01)

Prospective investigation of change in the prostate-specific antigens after various urologic procedures
by: Park SC, et al.
Published: (2015-07-01)

USE OF PROSTATIC SPECIFIC ANTIGEN AS A PREDICTOR OF THE LONG-TERM RESULTS OF BRACHYTHERAPY FOR PROSTATE CANCER
by: S. A. Ivanov, et al.
Published: (2014-08-01)

USE OF PROSTATIC SPECIFIC ANTIGEN AS A PREDICTOR OF THE LONG-TERM RESULTS OF BRACHYTHERAPY FOR PROSTATE CANCER
by: S. A. Ivanov, et al.
Published: (2014-08-01)

Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90
by: Alex Henke, et al.
Published: (2016-08-01)

The effects of specific expression of apoptin under the control of PSES and PSA promoter on cell death and apoptosis of LNCaP cells
by: Vida Mohammadi, et al.
Published: (2017-12-01)

What Should Be the Prostate Specific Antigen Threshold for Prostate Biopsy?
by: Hasan Deliktaş, et al.
Published: (2017-06-01)

The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
by: Bai X, et al.
Published: (2020-08-01)

Prostatic specific antigen for prostate cancer detection
by: Lucas Nogueira, et al.
Published: (2009-10-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

Knowledge, attitudes and practices of Ugandan men regarding prostate cancer
by: H Nakandi, et al.
Published: (2013-12-01)

Analysis of the Correlationship between Prostate Specific Antigen Related Variables and Risk Factor in Patients with Prostate Carcinoma
by: Daoyuan Wang, et al.
Published: (2015-01-01)

THE PRETREATMENT PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME: CLINICAL AND PROGNOSTIC VALUES IN PATIENTS WITH PROSTATE CANCER
by: G. M. Zharinov, et al.
Published: (2014-07-01)

THE PRETREATMENT PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME: CLINICAL AND PROGNOSTIC VALUES IN PATIENTS WITH PROSTATE CANCER
by: G. M. Zharinov, et al.
Published: (2014-07-01)

The routine use of prostate-specific antigen for early detection of cancer prostate in India: Is it justified?
by: Deepak Dubey
Published: (2009-01-01)

PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium
by: Zi-Jian Song, et al.
Published: (2021-01-01)

Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center- a retrospective study
by: Tarek Ajami, et al.
Published: (2021-02-01)

Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer
by: Weitao Song, et al.
Published: (2015-01-01)

Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values
by: Hasan Yilmaz, et al.
Published: (2015-06-01)

A ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

A ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
by: Michael Tzeng, et al.
Published: (2021-08-01)

Possibility of using PCA3 score without prostate massage in urine for diagnosing prostate cancer
by: A. A. Musaelyan, et al.
Published: (2021-02-01)

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia
by: Yasuhide Kitagawa, et al.
Published: (2015-06-01)

Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors
by: Kyo Chul Koo, et al.
Published: (2013-09-01)

APHIG: a new multiparameter index for prostate cancer
by: N. S. Sergeeva, et al.
Published: (2016-12-01)

Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?
by: Gokhan Koc, MD, et al.
Published: (2017-01-01)